These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7592186)

  • 1. Are all carbapenems created equal?
    Simpson IN; Hunter R; Govan JR
    J Antimicrob Chemother; 1995 May; 35(5):707-8. PubMed ID: 7592186
    [No Abstract]   [Full Text] [Related]  

  • 2. Are all carbapenems created equal?
    Baxter IA; Lambert PA
    J Antimicrob Chemother; 1995 May; 35(5):708-9. PubMed ID: 7592187
    [No Abstract]   [Full Text] [Related]  

  • 3. Pneumococcal susceptibility to meropenem.
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 1996 May; 37(5):1036-7. PubMed ID: 8737158
    [No Abstract]   [Full Text] [Related]  

  • 4. Susceptibility testing of Stenotrophomonas maltophilia to carbapenems.
    Howe RA; Wilson MP; Walsh TR; Millar MR
    J Antimicrob Chemother; 1997 Jul; 40(1):13-7. PubMed ID: 9249199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro susceptibility of Haemophilus influenzae to meropenem compared with imipenem, five other beta-lactams, chloramphenicol and ciprofloxacin.
    Powell M; Seetulsingh P; Williams JD
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():175-81. PubMed ID: 2808206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group.
    Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC
    Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivities to four carbapenems of bacteria isolated from patients with refractory complicated urinary tract infections and the detection of carbapenemase-producing Pseudomonas aeruginosa.
    Matsumoto T; Kumazawa J; Nagayama A
    J Antimicrob Chemother; 1996 Aug; 38(2):322-4. PubMed ID: 8877553
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative in vitro activity of carbapenems against clinical isolates of Acinetobacter baumannii.
    Douraghi M; Ghalavand Z; Nateghi Rostami M; Zeraati H; Aliramezani A; Rahbar M; Mohammadzadeh M; Ghourchian S; Boroumand MA; Abdollahi A
    J Appl Microbiol; 2016 Aug; 121(2):401-7. PubMed ID: 27171885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp.
    Yazawa K; Mikami Y; Ohashi S; Miyaji M; Ichihara Y; Nishimura C
    J Antimicrob Chemother; 1992 Feb; 29(2):169-72. PubMed ID: 1506332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial properties of meropenem towards clinical isolates, beta-lactamase producers and laboratory mutants.
    Wiedemann B; Zühlsdorf M
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():197-205. PubMed ID: 2681124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A novel carbapenem active against imipenem resistant strains of Pseudomonas aeruginosa].
    Sazykin YuO
    Antibiot Khimioter; 1997; 42(8):42. PubMed ID: 9412413
    [No Abstract]   [Full Text] [Related]  

  • 12. In vitro activities of three carbapenems against recent bacterial isolates from severely ill patients at Swedish hospitals.
    Fraenkel CJ; Ullberg M; Bernander S; Ericson E; Larsson P; Rydberg J; Törnqvist E; Melhus A
    Scand J Infect Dis; 2006; 38(10):853-9. PubMed ID: 17008228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BO-2727, meropenem and imipenem disc diffusion susceptibility testing criteria.
    Barry AL; Fuchs PC
    J Antimicrob Chemother; 1995 Aug; 36(2):444-6. PubMed ID: 8522478
    [No Abstract]   [Full Text] [Related]  

  • 14. Are all carbapenems created equal?
    Iaconis JP; Nadler HL; Pitkin DH; Sheikh W
    J Antimicrob Chemother; 1994 Sep; 34(3):443-4. PubMed ID: 7530243
    [No Abstract]   [Full Text] [Related]  

  • 15. In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa.
    Giamarellos-Bourboulis EJ; Grecka P; Giamarellou H
    J Antimicrob Chemother; 1996 Aug; 38(2):287-91. PubMed ID: 8877544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem.
    Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH
    Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial activity of meropenem against gram-negative bacteria with a permeability defect and against staphylococci.
    Kitzis MD; Acar JF; Gutmann L
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():125-32. PubMed ID: 2808204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro antibacterial activities of doripenem, imipenem, and meropenem against recent Streptococcus pneumoniae isolates.
    Baek JY; Ko KS; Kang CI; Song JH; Peck KR
    Diagn Microbiol Infect Dis; 2011 Nov; 71(3):297-300. PubMed ID: 21855246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
    Tasaka K; Ishida A; Chinzei T
    Jpn J Antibiot; 2002 Apr; 55(2):181-6. PubMed ID: 12071095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stability of doripenem, imipenem and meropenem at elevated room temperatures.
    Keel RA; Sutherland CA; Crandon JL; Nicolau DP
    Int J Antimicrob Agents; 2011 Feb; 37(2):184-5. PubMed ID: 20702066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.